BLPH - Bellerophon gets green light from China NMPA to conduct phase 3 trial of fibrotic interstitial lung disease treatment

• Bellerophon Therapeutics ( NASDAQ: BLPH ) announced the clearance of its Investigational New Drug ( IND ) application to conduct a Phase 3 clinical trial of INOpulse to treat fibrotic interstitial lung disease (fILD) in China.
• ( BLPH ) is trading 4.2% higher premarket.
• The study will use Moderate to Vigorous Physical Activity (MVPA) as the primary endpoint and be conducted in collaboration with Bellerophon’s Chinese partner, Baylor BioSciences.
• "INOpulse has significant potential in treating various diseases associated with pulmonary hypertension and the clearance of this IND brings us one step closer to a new treatment option for the underserved fILD patient community in Greater China," the company said .

For further details see: